Protocol Overview
Synergy & Mechanism
Oral BPC-157 Mechanism
Oral BPC-157 (arginate salt) is acid-stable and directly contacts the gastrointestinal mucosa, providing localized healing for gut conditions including leaky gut, IBS, and gastric ulcers. It also exerts systemic effects through the gut-brain axis, modulating dopamine and serotonin systems, and provides whole-body anti-inflammatory benefits that complement injectable healing.
Injectable BPC-157 Synergy
Subcutaneous BPC-157 concentrates healing activity at the injection site, directly promoting angiogenesis, growth factor upregulation, and tissue regeneration in musculoskeletal injuries. The dual-route approach ensures comprehensive coverage: oral for systemic/gut healing, injectable for targeted local repair at injury sites.
Combined Dosing Protocol
Standard
BPC-157 oral 500mcg 2x/day
BPC-157 SubQ 250mcg 1x/day
AM oral+SubQ, PM oral
6-8 weeks
Gut-Focus
BPC-157 SubQ 250mcg EOD
AM/PM oral, AM SubQ
6 weeks
Injury-Focus
BPC-157 oral 250mcg 1x/day
BPC-157 SubQ 500mcg 1x/day
AM oral, AM SubQ
4-6 weeks
Reconstitution & Preparation
Oral BPC-157 Preparation
BPC-157 Arginate capsules: 250mcg or 500mcg
No reconstitution needed
Take on empty stomach for best absorption
Store at room temperature
Injectable BPC-157 Preparation
BPC-157 vial: 5mg lyophilized
Reconstitute with 2mL BAC water = 2,500mcg/mL
250mcg dose = 10 units on insulin syringe
Refrigerate, use within 30 days
Stacking Schedule (AM/PM Timing)
AM Protocol
6:30 AM (fasted): BPC-157 oral 500mcg capsule
7:00 AM: BPC-157 SubQ 250mcg near injury site
Wait 30 min before eating
PM Protocol
Before bed (fasted): BPC-157 oral 500mcg
Take at least 2 hours after last meal
Oral BPC-157 works overnight for GI healing
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Injection site redness (mild, transient)
Mild nausea with oral form (uncommon)
Mild dizziness (rare)
GI adjustment during first few days
BPC-157 has excellent safety across both oral and injectable routes.
Precautions
May promote angiogenesis in tumors (theoretical)
Avoid if active cancer
Limited human clinical trial data
Oral bioavailability varies between manufacturers
Blood Work Recommendations
Inflammatory
CRP, ESR
Baseline, Week 4
GI Markers
Calprotectin (stool), lactulose/mannitol
Baseline, Week 6
Basic
CBC, CMP
Stool calprotectin tracks GI inflammation improvement. CRP and ESR track systemic inflammation from both routes.
Related Protocols & Tools